RxDoctor Payments Data

Sunn Sunn Thaw, MD

Hematology & Oncology · Woodbury, MNNPI 1629277785

Payments from drug & device makers

$7,588in general payments, 2019–2025

Across 11 payments — averaging $689.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$2K
  • Beigene USA, Inc.$2K
  • Seagen Inc.$1K
  • Incyte Corporation$860
  • Blueprint Medicines Corporation$788
  • AstraZeneca$670
  • plus $23 from 2 others

What the payments were for

  • Consulting fees$7,42198%
  • Food & beverage$1121%
  • Education$551%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,588 in reported general payments places this provider in the 55th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$94,498
Medicare patients
273
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide47$862,827
TagrissoOsimertinib Mesylate24$410,224
ImbruvicaIbrutinib29$375,798
IbrancePalbociclib18$281,729
NinlaroIxazomib Citrate12$158,807
KisqaliRibociclib Succinate12$151,491
VenclextaVenetoclax14$45,673
EliquisApixaban39$29,116
XareltoRivaroxaban16$15,086
CreonLipase/Protease/Amylase12$13,686
Anastrozole400$9,085
Exemestane45$4,872
Imatinib Mesylate15$4,062
Tamoxifen Citrate84$3,456
Letrozole95$2,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$670$410,22424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 193 hematology & oncology providers in Minnesota.

Other hematology & oncology in Woodbury

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →